Although VEGF inhibitors suppress tumor progression, the therapeutic effects are sometimes limited; paradoxically, VEGF inhibitors can promote aggressiveness by increasing tumor hypoxia or the number of abnormalized vessels (5–8). This evidence concerns the gene VEGFA and neoplasm.